Outlook Therapeutics, Inc. Q3 FY2024 earnings call

• Mission: Achieve first approval for ophthalmic bevacizumab for retina diseases in EU, UK, US.
• Europe: Received marketing authorization in EU and UK; advancing market access, inventory planning, and partner discussions for launch in first half of 2025.
• US: NORSE EIGHT trial has 359 of 400 subjects enrolled, expected top line results in Q4 2024, BLA resubmission to FDA in Q1 2025; completed Type C and D meetings with FDA, addressing CMC items.
• Financials: Cash position ~$32 million as of June 30, 2024; expected $107 million from warrant exercises to support operations through 2025; R&D expenses reduced in Q3 2024; G&A expenses increased due to pre-launch Europe expenses.

No detailed product segment financial performance provided in the transcript as the focus is on drug development and regulatory progress rather than product revenue breakdowns.

• Expect BLA resubmission to FDA in Q1 2025 upon completion of NORSE EIGHT enrollment.
• Cash position combined with warrant proceeds should support operations through calendar 2025.
• R&D expenses expected to continue at current levels for the next quarter.

• Forward-looking statements involve risks and uncertainties; actual results may differ from expectations.
• Factors from SEC filings could cause material differences in actual results.
• Clinical trial enrollment and regulatory approval timelines are uncertain.

Q: Julian Harrison asked about enrollment details in NORSE EIGHT.

A: Russell Trenary said they have dozens in screening, enough to reach 380 patients and expect to finish enrollment by end of third quarter.

Q: Will Hidell inquired about UK NICE process.

A: Russell Trenary stated they have a well-informed dossier with NICE and are going through the process, with pricing to be known later in the year.

Q: Timothy Chiang asked about Type C and D meetings with FDA.

A: Russell Trenary said timing of BLA filing is tied to enrollment completion, discussions with FDA were positive, and CMC items were addressed.

Q: Douglas Tsao asked about BLA filing timing and European launch inventory.

A: Russell Trenary said BLA timing is due to enrollment pace, and inventory is being tracked for shelf life extension for European and potential US launch.

Q: Daniil Gataulin asked about EU off-label use and launch checklist.

A: Russell Trenary discussed varying EU market dynamics for off-label use and mentioned market access, HTA work, and salesforce planning as launch checklists for first half of 2025.